REGN

Regeneron Pharmaceuticals
D

REGN

542.46
USD
-7.51
(-1.37%)
مغلق
حجم التداول
55,771
الربح لكل سهم
36
العائد الربحي
0.32
P/E
14
حجم السوق
58,566,963,503
أصول ذات صلة
AMGN
AMGN
-3.67
(-1.23%)
294.70 USD
BIIB
BIIB
-3.731
(-2.90%)
124.999 USD
BMY
BMY
-0.700
(-1.46%)
47.375 USD
GILD
GILD
-0.620
(-0.57%)
108.190 USD
INCY
INCY
-1.120
(-1.62%)
67.850 USD
MRK
MRK
-1.540
(-1.89%)
79.970 USD
PFE
PFE
-0.135
(-0.55%)
24.460 USD
VRTX
VRTX
-3.54
(-0.76%)
459.83 USD
المزيد
الأخبار المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).